

Strain Differences in Bloodstream and Skin Infection MRSA isolated between 2019-2021 in a Single Health System

Katrina S. Hofstetter¹, Natasia F. Jacko², Margot J. Shumaker², Brooke M. Talbot¹, Robert A. Petit III^{1#}, Timothy D. Read¹, Michael Z. David^{2*}

¹ Division of Infectious Diseases, Department of Medicine, Emory University, Atlanta, Georgia, USA

² Division of Infectious Diseases, Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA

Current address: Wyoming Public Health Laboratory, Cheyenne, Wyoming, USA

* Corresponding author,
Michael Z. David - michdav@pennmedicine.upenn.edu

Keywords: *Staphylococcus aureus*, whole genome sequencing, SSTI, bacteremia, clonal complex, CC5, CC8

KSH: katrina.sierra.hofstetter@emory.edu; ORCID: 0000-0003-0389-2027

NFJ: natasia.jacko@pennmedicine.upenn.edu; ORCID: 0000-0002-8295-7951

MJS: margotshumaker@gmail.com; ORCID 0000-0002-5993-7549

BMT: brooke.talbot@emory.edu; ORCID orcid.org/0000-0001-5246-7209

RAP III: rpetit@emory.edu; ORCID; 0000-0002-1350-9426

TDR: tread@emory.edu; ORCID:0000-0001-8966-9680

MZD: michdav@pennmedicine.upenn.edu ORCID; 0000-0002-1926-7800

1 **Abstract:**

2 *S. aureus* is a common cause of skin and soft tissue infections (SSTIs) and has recently become
3 the most common cause of bloodstream infections (BSIs), but whether the strains causing these
4 two clinical syndromes overlap has not been studied adequately. USA300/500 (clonal complex
5 [CC] 8-ST8) and USA100 (CC5-ST5) have dominated among methicillin-resistant *S. aureus*
6 (MRSA) strains in the U.S. since the early 2000s. We compared the genomes of unselected
7 MRSA isolates from 131 SSTIs with those from 145 BSIs at a single U.S. center in overlapping
8 periods in 2018-2021. CC8 MRSA was more common among SSTIs and CC5 was more common
9 among BSIs, consistent with prior literature. Based on clustering genomes with a threshold of
10 15 single nucleotide polymorphisms (SNPs), we identified clusters limited to SSTI patients and
11 separate clusters exclusively comprising BSI patients. However, we additionally identified 8
12 outbreak clusters that included at least one SSTI and one BSI isolate. This suggests that virulent
13 MRSA strains are transmitted from person-to-person locally in the healthcare setting and the
14 community and that single lineages are often capable of causing both SSTIs and BSIs.

15

16 **Introduction**

17 *Staphylococcus aureus* asymptomatically colonizes the nares of 28-40% of the human
18 population [1], [2]. *S. aureus* is a common cause of skin and soft tissue infections (SSTIs) [3], and
19 has recently become the most common cause of bloodstream infections (BSIs) [4]. Nasal
20 colonization of patients has been associated with an increased risk of both BSIs [5] and SSTIs
21 [2], [3]. Colonization provides a reservoir from which *S. aureus* can access the bloodstream after
22 a minor skin injury, trauma, surgery, or a viral infection [3], [4].

23 Community-associated (CA-) MRSA infections in the U.S., epidemiologically defined as
24 those occurring in subjects with no recent healthcare exposures, have been most often
25 reported in younger, healthy individuals [3], [6]. Healthcare-associated (HA-) MRSA infections,
26 in contrast, are more likely to be diagnosed in older patients with comorbidities and are often
27 invasive infections such as BSI or pneumonia [6]. Since at least 2004, the most often isolated
28 MRSA strains in the US have belonged to clonal complex (CC)8 and CC5 [7]. USA300, which
29 belongs to multilocus sequence type (ST) 8 (included in CC8), was initially associated with CA-
30 MRSA infections, but since 2005 it has increasingly been recognized also as the cause of
31 nosocomial infections [3], [6], [8]. USA300 has become the most common MRSA strain
32 circulating in the US [9]. USA500 is a closely related CC8 strain type that is easily distinguished
33 from USA300 by whole genome sequencing (WGS) [10], [11]. USA100 (usually ST5, which
34 belongs to CC5) is most often a HA-MRSA strain. However, it has also been uncommonly
35 isolated from epidemiologically defined CA-MRSA infections and from nasal carriage in subjects
36 with no prior healthcare exposures [12]. Thus, there are no strain types that consistently
37 distinguish between epidemiologically defined CA-MRSA and HA-MRSA infections [13].

38 Reports from the last 15 years indicate that the majority of MRSA SSTIs in the U.S. have
39 their onset in the community and are caused by USA300 [3], [7], [8]. One study of strains
40 reported in the published literature found that in 2002-2013, 62% of SSTIs were caused by
41 USA300 and 19% by the second most common strain type, USA100 [8]. The prevalence of
42 USA300 among BSI isolates may be increasing [14].

43 To understand the relationships between SSTI and BSI isolates, we performed WGS on
44 SSTI and BSI MRSA strains from patients at two hospitals of the University of Pennsylvania from

45 2018-2020. We first compared the phylogenetic structure of MRSA isolates from SSTIs and BSIs.
46 We then assessed whether any of these genomes were closely associated with one another,
47 which would suggest recent transmission among study subjects. Among the SSTI isolates alone,
48 three clusters were identified. We additionally identified eight clusters containing strains from
49 both SSTI and BSI cases, suggesting epidemiological overlap and the spread of MRSA strains
50 between patients with HA- and CA-MRSA infections within a single geographic area.

51

52 **Methods**

53 **Patient and isolate selection**

54 MRSA isolates were collected by the Hospital of the University of Pennsylvania (HUP)
55 Clinical Microbiology Laboratory (CML) from routine clinical specimens obtained from
56 outpatient clinics, emergency departments and inpatient units at HUP or the Penn Presbyterian
57 Medical Center (PPMC). All MRSA isolates from SSTIs were biobanked in December 2018 -
58 February 2021. After screening of the electronic medical record (EMR) to document that a
59 MRSA isolate was from an SSTI, each source patient was contacted and offered enrollment in
60 SEMAPHORE (Study of the Evolution of MRSA, Antibiotics, Persistence Having the Outcome of
61 REcurrence), which is an NIH-funded study to determine risk factors for recurrent *S. aureus*
62 infections during a 2-year period of follow-up. Approximately 28% of eligible subjects with SSTIs
63 were enrolled prospectively in SEMAPHORE between December 2018 and February 2021 and
64 were included in the present study. Separately, sequential patients with a MRSA BSI diagnosed
65 in July 2018-August 2020 were included in a retrospective study (BREGOS, the MRSA
66 Bacteremia Retrospective Epidemiologic and Genomic Outcomes Study [15]).

67 For both SSTI and BSI patients, collection of demographic data from the electronic
68 medical record included age, race, sex, zip code of home residence, site of collection
69 (emergency department, outpatient clinic, or inpatient), infection type, anatomic source of
70 infection, and epidemiological classification (CA-, HA- or community-onset, healthcare-
71 associated [HACO]). Infections in subjects who had a first positive culture obtained >48 hours
72 after admission to a hospital were classified as HA-MRSA. If an infection occurred in a subject
73 <48 hours after admission to a hospital or from an outpatient, but who had one or more
74 specific healthcare exposures (hemodialysis, surgery, nursing home stay, hospitalization within
75 the last year or presence of an indwelling central venous catheter at the time of diagnosis),
76 subjects were classified as having a HACO-MRSA infection. Infections were classified as CA-
77 MRSA if the patient had none of these healthcare exposures and was cultured as an outpatient
78 or <48 hours after hospital admission. For BSI patients, the Pitt Bacteremia Score and in-
79 hospital mortality were recorded. The study was approved by the University of Pennsylvania
80 IRB.

81

82 **DNA sequencing**

83 Isolates from HUP CML were stored prospectively at -80C. To prepare DNA for
84 sequencing, frozen cultures were streaked on blood agar plates and incubated overnight at
85 37°C. Single isolates were passaged onto fresh blood agar plates before single colonies were
86 isolated for sequencing. Isolates were sequenced at the Children's Hospital of Philadelphia
87 Penn/CHOP Microbiome Center. Sequence libraries were prepared using the Illumina Nextera

88 kit and sequenced by Illumina Hi-seq. Sequences for the SSTI and BSI are available on NCBI
89 Sequence Read Archive (PRJNA918392, PRJNA751847, respectively).

90

91 **Bioinformatic analysis**

92 The Bactopia pipeline was used to assemble fastq files, call MLST and SCCmec type,
93 along with identifying variants [16]. CCs were assigned based on ST type and PubMLST. If a CC
94 was not available for an ST the ST was used in place of the CC. All CC8 strains were classified as
95 USA300 or USA500 based on the primer sequencing and the presence of PVL genes and
96 arginine catabolic mobile element (ACME) [10]. To generate Maximum likelihood trees, core
97 alignments were made using Parsnp (v 1.7.4) [17] and trees were created using IQ-Tree (v
98 2.2.0.3) [18]. The GGTree package was used for visualization and figure generation [19]. Trees
99 were rooted to GCF_000144955.1_ASM14495v1, and both a USA300 reference
100 (GCF_022226995.1_ASM2222699v1) and USA500 reference
101 (GCF_016916765.1_ASM1691676v1) were included. To identify outbreak clusters, we identified
102 core genomes with fewer than 15 SNP differences, pairwise distances were calculated using
103 Disty McMatrixface (<https://github.com/c2-d2/disty>). We used SCOARY2
104 (<https://pubmed.ncbi.nlm.nih.gov/27887642/>) with default parameters to assess for an
105 association of any *S. aureus* accessory gene with BSI or SSTI.

106

107 **Statistical Analysis**

108 Patient and isolate characteristics were compared for SSTI and BSI cohorts. The Chi-
109 square test was used when testing for associations of demographic and clinical data with strain

110 types with categorical data, unless sample sizes were small (<5 in a cell), in which case the
111 Fisher exact test was performed. Comparisons of continuous data were made using the
112 Wilcoxon rank-sum test. All statistical analysis was performed using R v4.2.2 [20].

113

114 **Results**

115 During the study period, 131 subjects with SSTIs were enrolled, and 145 sequential
116 subjects with a BSI were included in the BREGOS study [15]. SSTI and BSI patients did not differ
117 significantly in distribution by age or race (**Table 1, Supplemental Figure 1**). However, SSTI
118 patients were more likely to have CA-MRSA infections and less likely to have HA- or HACO-
119 MRSA infections than BSI patients. SSTI patients were more likely to have been diagnosed with
120 the infection as an outpatient (46% vs. 2%) or in the emergency department and sent home
121 (27% vs. 3%) than BSI patients. BSI patients were nearly all diagnosed in the inpatient setting
122 (95%) (**Table 1**). Abscesses were the most common type of SSTI (52%, n = 68), followed by
123 surgical site infections (14%, n = 18) and infected wounds (12%, n = 16). Among BSI with a
124 known source of infection, the most common sources were a skin site (19%) or a central venous
125 catheter infection (14%) (**Table 2, Figure 1**). In-hospital mortality for BSI patients was 15%
126 (22/145).

127

128 **Comparing strain types among SSTI and BSI MRSA Isolates**

129 SSTI isolates were assigned to 14 STs by genome-based MLST. CC8 and CC5 were the
130 most abundant clonal complexes among the SSTI isolates, accounting for the vast majority of all
131 MRSA strains, with CC8 being the most prevalent (102/131, 78%) and CC5 second most

132 (20/131, 15%) (**Table 1**). Among abscesses, CC8 strains were by far the most common (60/68,
133 88%, p-value >0.01) (**Figure 1**). BSI isolates belonged to 5 CCs (CC8, CC5, CC72, CC78, and CC30),
134 and 1 ST was not included in a CC (ST87). The BSI isolates were in 13 STs. As for SSTI isolates,
135 the majority of BSI isolates were CC5 or CC8 (55/145, 38%, and 79/145, 54%, respectively),
136 although the CC8 strains made up a significantly larger proportion of the SSTI than the BSI
137 strains (p <0.1) (**Table 1, Figure 1**).

138 We compared the genomes of the 131 SSTI isolates to 145 BSI isolates [15]. All of the
139 CC8 strains were subtyped into either USA300 (n=101 SSTI/n= 69 BSI) or USA500 [10] (n=1
140 SSTI/n= 10 BSI). SSTI and BSI strains belonging to the same ST did not form separate subclades
141 but instead were polyphyletic (**Figure 2**). The principal difference between the groups of strains
142 was in the balance of the genotypes: CC8 were overrepresented in SSTI (102/131, 78%, p value
143 >0.01) compared to CC5 (21/131, 16%) (**Figure 1, Table 1**). CC5, in contrast, were more often
144 found as a cause of BSIs than of SSTIs (55/145, 38%).

145 Comparing the antimicrobial susceptibilities of BSI isolates to SSTI isolates, the patterns
146 are quite similar overall. However, BSI isolates were less likely to be susceptible to clindamycin
147 (59% vs. 73%), erythromycin (11% vs. 17%), and trimethoprim/sulfamethoxazole (93% vs.
148 100%) (**Table 3**). These associations were confounded by the different strain backgrounds
149 associated with SSTI/BSI and there was not a significant association between AMR genes and
150 disease state when adjusting for phylogeny using the pangenome GWAS tool SCOARY2.

151

152 **Transmission clusters among SSTI and BSI strains**

153 While it has been reported that SSTI can serve as a reservoir for BSI, it is not known if
154 MRSA causing BSIs and MRSA causing SSTIs, even within the same clonal complexes, are distinct
155 from one another. We thus investigated, among isolated genomes from our study, how closely
156 strains from different patients with BSIs and SSTIs were related. Several studies have indicated
157 that a 15 SNP difference threshold can be used to cluster isolates into epidemiologically linked
158 groups that shared the same common ancestor in the past few years [15], [21]–[25]. In our
159 combined group of 276 isolates from SSTI and BSI, we identified 16 clusters containing between
160 2 and 4 isolates using the 15 SNP threshold, representing 13% (35/276) of all isolates. The
161 correlation of pairwise distances between the phylogenetic tree and the distance matrix was
162 0.997 (**Supplemental Figure 2**). Three clusters contained only strains from SSTIs (all CC8) and in
163 five clusters all strains were from BSIs (two CC8 and three CC5). Eight outbreak clusters
164 contained at least one BSI isolate and one SSTI isolate, seven of which were CC8 and one was
165 CC5 (**Figure 2 B,C, Table 4**). Comparisons of the electronic medical records revealed that one
166 cluster that contained both a BSI and SSTI came from the same patient (cluster 15), while the
167 remaining seven came from different patients. This result suggested frequent epidemiological
168 overlap between patients with SSTIs in the community and BSI in hospitals.

169 **Discussion**

170 The results of this study highlight divergent trends in infections caused by the two most
171 common *S. aureus* clonal complexes currently isolated in the USA. CC8 isolates were strongly
172 associated with SSTI and CC5 with BSIs. CC8 isolates that are subtyped to USA300 were the
173 most common strain type in our study population.

174 The USA300 MRSA strain likely emerged in the early 1970s and spread rapidly during the
175 1990s and 2000s across North America to achieve its current predominant position among
176 MRSA strain types [7], [26]. One study of 224 ST8 genomes suggested that the USA300 clone
177 descended from an ST8 progenitor originating in central Europe in the 19th century, with an
178 introduction to North America in the early 20th century, while gradually acquiring its typical
179 genomic and virulence characteristics such as PVL, SCCmec type IVa, and the arginine catabolic
180 mobile element (ACME) [27]. Another study of USA300 MRSA genomes suggested that the
181 USA300 clone first emerged on the East Coast of the US, and perhaps in Pennsylvania [28].
182 Although USA300 MRSA was originally identified as a “CA-MRSA strain”, it was soon also
183 recognized as a nosocomial pathogen as early as 2005 [6], [8], [29], [30]. Indeed, USA300 has
184 since become the leading cause of BSI in the US, which are usually classified as HA- or HACO-
185 MRSA infections [4]. With this shift from the community to the healthcare setting, we
186 previously demonstrated among 616 sequential MRSA isolates from the University of Chicago
187 Medical Center in 2004-5 that there was already a poor correlation between the typical
188 genotypic characteristics of “CA-MRSA” strain types, such as ST8, carrying SCCmec type IV, PVL
189 gene carriage, or lack of a multidrug resistance phenotype with the CDC’s epidemiologic criteria
190 for CA-MRSA infections [13].

191 In the current study, carried out in Philadelphia (750 miles from Chicago), and with
192 isolates collected about 15 years later, the ST5 (USA100) and ST8 (USA300 or USA500) strains
193 continue to dominate among MRSA isolates obtained from both blood and SSTIs. Many other
194 U.S. and Canadian studies with isolates collected between 2003 and 2018 have shown similar
195 results, with a generally increasing percent of BSIs and SSTIs caused by USA300/USA500 and a

196 decreasing percent caused by USA100 [14], [31]–[40]. In a cohort of 276 MRSA SSTI and BSI
197 patients at a single U.S. institution in 2018-2021, CC5 and CC8 strains predominated. In fact,
198 93% of all SSTI strains were either CC5 or CC8, and CC8 was significantly more common among
199 SSTI than among BSI patients. Many epidemiologic characteristics of patients and their MRSA
200 isolates were consistent with literature from the past 15 years, indicating only slowly shifting
201 trends in relative strain prevalence during this period. Remarkably, we found that closely
202 clonally related strains of MRSA caused both BSIs and SSTIs in different patients in our cohort,
203 suggesting that the pathogenesis of invasive infections in very different human tissues may not
204 require highly adapted strains. We do not yet know to what extent genetic differences between
205 the clonal complexes (e.g., carriage of virulence genes such as arginine catabolic mobile
206 element or PVL) play a role in the observed differences in sites of infection or if these
207 differences.

208 We found in this study that abscesses are the most common type of SSTI, and they were
209 significantly enriched among the infections caused by CC8 strains, an observation consistent
210 with previous literature on CA-MRSA strains [41]. Also, in patients greater than 50 years of age
211 who presented with an SSTI, we observed a higher prevalence of CC5 strains compared with
212 younger patients. This trend could not be explained by differences in any specific infection type,
213 although we did find that patients greater than 50 years old in our cohort were more likely than
214 younger patients to have surgical site infections, and infected ulcers and wounds. The older
215 population is likely to have had more healthcare-associated risk factors than those under 50,
216 and CC5 may be more prevalent in the older cohort because CC5 strains tend to cause
217 infections more often in hospital, rather than community, settings.

218 There have been few previous studies examining the genomes of MRSA infections from
219 different anatomic sites at a single center. We identified potential MRSA transmission clusters
220 using a conservative threshold of 15 or fewer SNPs. Three clusters were of only SSTI strains,
221 suggesting small-scale outbreaks among the patients. There were also (five) clusters of only BSI
222 strains, representing probable healthcare transmission, as reported by Talbot et al [15].
223 Surprisingly, given that we showed BSI and SSTI were commonly caused by different *S. aureus*
224 clones, we found that 50% of the clusters contained both disease types. This result suggested
225 epidemiologic linkage between BSI and SSTI may be more frequent than previously realized.
226 There is literature that discusses potential BSI reservoirs being concurrent SSTI [14] and
227 colonization of the nares [5]. A prior SSTI within the last year also increased the risk of a BSI
228 [14]. Thus, it is possible that some BSI patients in our study became bacteremic after a MRSA
229 SSTI; however, only a small number of patients had a known SSTI as a source of BSI in our
230 cohort.

231 Limitations of our study include the relatively small size of the cohorts examined and the
232 lack of epidemiologic data about potential interactions among subjects. Also, the study was
233 performed only at a single center and thus may not be generalizable.

234 Our work highlights the importance of considering strain background in future studies of
235 *S. aureus* to understand the relative roles of strain and patient characteristics in determining
236 sites of infection.

237

238 **Conflicts of interest**

239 The authors report no conflicts of interest.

240 Funding

241 The authors were supported by the National Institute of Health (NIH) (grant number RO1
242 AI139188)

243 References

- 244
- 245 [1] Corey P. Parlet, M. M. Brown, and A. R. Horswill, "Commensal Staphylococci Influence
246 Staphylococcus aureus Skin Colonization and Disease," *Physiol. Behav.*, vol. 176, no. 3,
247 pp. 139–148, 2017, doi: 10.1016/j.tim.2019.01.008.Commensal.
- 248 [2] J. Kluytmans, A. van Belkum, and H. Verbrugh, "Nasal carriage of Staphylococcus aureus:
249 epidemiology, underlying mechanisms, and associated risks," *Clin. Microbiol. Rev.*, vol.
250 10, no. 3, pp. 505–520, 1997, doi: 10.1128/cmr.10.3.505.
- 251 [3] S. D. Kobayashi, N. Malachowa, and F. R. Deleo, "Pathogenesis of Staphylococcus aureus
252 abscesses," *Am. J. Pathol.*, vol. 185, no. 6, pp. 1518–1527, 2015, doi:
253 10.1016/j.ajpath.2014.11.030.
- 254 [4] E. J. M. Raineri, D. Altulea, and J. M. van Dijk, "Staphylococcal trafficking and infection—
255 from 'nose to gut' and back," *FEMS Microbiol. Rev.*, no. March, pp. 1–22, 2021, doi:
256 10.1093/femsre/fuab041.
- 257 [5] H. F. L. Wertheim *et al.*, "Risk and outcome of nosocomial Staphylococcus aureus
258 bacteraemia in nasal carriers versus non-carriers," *Lancet*, vol. 364, no. 9435, pp. 703–
259 705, 2004, doi: 10.1016/S0140-6736(04)16897-9.
- 260 [6] M. Z. David and R. S. Daum, "Community-associated methicillin-resistant Staphylococcus
261 aureus: Epidemiology and clinical consequences of an emerging epidemic," *Clin.
262 Microbiol. Rev.*, vol. 23, no. 3, pp. 616–687, 2010, doi: 10.1128/CMR.00081-09.
- 263 [7] P. J. Planet *et al.*, "Architecture of a Species: Phylogenomics of Staphylococcus aureus,"
264 *Trends Microbiol.*, vol. 25, no. 2, pp. 153–166, 2017, doi: 10.1016/j.tim.2016.09.009.
- 265 [8] M. Carrel, E. N. Perencevich, and M. Z. David, "USA300 methicillin-resistant
266 Staphylococcus aureus, United States, 2000–2013," *Emerg. Infect. Dis.*, vol. 21, no. 11,
267 pp. 1973–1980, 2015, doi: 10.3201/eid2111.150452.
- 268 [9] D. J. Diekema *et al.*, "Continued Emergence of USA300 Methicillin-Resistant
269 Staphylococcus aureus in the United States: Results from a Nationwide Surveillance
270 Study," *Infect. Control Hosp. Epidemiol.*, vol. 35, no. 3, pp. 285–292, Mar. 2014, doi:
271 10.1086/675283.
- 272 [10] J. R. Bowers *et al.*, "Improved Subtyping of Staphylococcus aureus Clonal Complex 8
273 Strains Based on Whole-Genome Phylogenetic Analysis," *mSphere*, vol. 3, no. 3, pp. 1–15,
274 2018, doi: 10.1128/msphere.00464-17.
- 275 [11] M. B. Frisch *et al.*, "Invasive Methicillin-Resistant," 2018.
- 276 [12] J. C. Roberts, "Community-associated methicillin-resistant staphylococcus aureus
277 epidemic clone USA100; more than a nosocomial pathogen," *Springerplus*, vol. 2, no. 1,
278 pp. 1–3, 2013, doi: 10.1186/2193-1801-2-133.
- 279 [13] M. Z. David *et al.*, "What is community-associated methicillin-resistant Staphylococcus

- 280 aureus?," *J. Infect. Dis.*, vol. 197, no. 9, pp. 1235–1243, 2008, doi: 10.1086/533502.
- 281 [14] P. Tattevin *et al.*, "Concurrent epidemics of skin and soft tissue infection and
282 bloodstream infection due to community-associated methicillin-resistant staphylococcus
283 aureus," *Clin. Infect. Dis.*, vol. 55, no. 6, pp. 781–788, 2012, doi: 10.1093/cid/cis527.
- 284 [15] B. M. Talbot *et al.*, "Unsuspected clonal spread of Methicillin-resistant Staphylococcus
285 aureus causing bloodstream infections in hospitalized adults detected using whole
286 genome sequencing," *Clin Infect Dis.* 2022 Dec 19;75(12):2104-2112. doi:
287 10.1093/cid/ciac339. PMID: 35510945; PMCID: PMC10200302..
- 288 [16] R. A. Petit and T. D. Read, "Bactopia: A flexible pipeline for complete analysis of bacterial
289 genomes," *mSystems*, vol. 5, no. 4, pp. 1–18, 2020, doi: 10.1101/2020.02.28.969394.
- 290 [17] T. J. Treangen, B. D. Ondov, S. Koren, and A. M. Phillippy, "The harvest suite for rapid
291 core-genome alignment and visualization of thousands of intraspecific microbial
292 genomes," *Genome Biol.*, vol. 15, no. 11, pp. 1–15, 2014, doi: 10.1186/s13059-014-0524-
293 x.
- 294 [18] L. T. Nguyen, H. A. Schmidt, A. Von Haeseler, and B. Q. Minh, "IQ-TREE: A fast and
295 effective stochastic algorithm for estimating maximum-likelihood phylogenies," *Mol. Biol.*
296 *Evol.*, vol. 32, no. 1, pp. 268–274, 2015, doi: 10.1093/molbev/msu300.
- 297 [19] G. Yu, D. K. Smith, H. Zhu, Y. Guan, and T. T. Y. Lam, "Ggtree: an R Package for
298 Visualization and Annotation of Phylogenetic Trees With Their Covariates and Other
299 Associated Data," *Methods Ecol. Evol.*, vol. 8, no. 1, pp. 28–36, 2017, doi: 10.1111/2041-
300 210X.12628.
- 301 [20] R. C. Team, "R: A language and environment for statistical computing. R Foundation for
302 Statistical Computing," 2022, [Online]. Available: <https://www.r-project.org/>.
- 303 [21] T. Azarian *et al.*, "Genomic epidemiology of Methicillin-resistant Staphylococcus aureus
304 in a neonatal intensive care unit," *PLoS One*, vol. 11, no. 10, pp. 1–20, 2016, doi:
305 10.1371/journal.pone.0164397.
- 306 [22] F. Coll *et al.*, "Definition of a genetic relatedness cutoff to exclude recent transmission of
307 methicillin-resistant Staphylococcus aureus: a genomic epidemiology analysis," *The Lancet*
308 *Microbe*, vol. 1, no. 8, pp. e328–e335, 2020, doi: 10.1016/S2666-5247(20)30149-X.
- 309 [23] D. W. Eyre *et al.*, "A pilot study of rapid benchtop sequencing of Staphylococcus aureus
310 and Clostridium difficile for outbreak detection and surveillance," *BMJ Open*, vol. 2, no. 3,
311 pp. 1–9, 2012, doi: 10.1136/bmjopen-2012-001124.
- 312 [24] J. A. Lees, M. Kendall, J. Parkhill, C. Colijn, S. D. Bentley, and S. R. Harris, "Evaluation of
313 phylogenetic reconstruction methods using bacterial whole genomes: a simulation based
314 study," *Wellcome Open Res.*, vol. 3, no. May, p. 33, 2018, doi:
315 10.12688/wellcomeopenres.14265.1.
- 316 [25] J. Stimson, J. Gardy, B. Mathema, V. Crudu, T. Cohen, and C. Colijn, "Beyond the SNP
317 Threshold: Identifying Outbreak Clusters Using Inferred Transmissions," *Mol. Biol. Evol.*,
318 vol. 36, no. 3, pp. 587–603, 2019, doi: 10.1093/molbev/msy242.
- 319 [26] C. M. Bianco *et al.*, "Pre-epidemic evolution of the MRSA USA300 clade and a molecular
320 key for classification," *Front. Cell. Infect. Microbiol.*, vol. 13, no. January, pp. 1–13, 2023,
321 doi: 10.3389/fcimb.2023.1081070.
- 322 [27] L. Strauß *et al.*, "Origin, evolution, and global transmission of community-acquired
323 Staphylococcus aureus ST8," *Proc. Natl. Acad. Sci. U. S. A.*, vol. 114, no. 49, pp. E10596–

- 324 E10604, 2017, doi: 10.1073/pnas.1702472114.
- 325 [28] L. Challagundla *et al.*, “crossm Epidemic Methicillin-Resistant Staphylococcus aureus,”
326 vol. 9, no. 1, pp. 1–15, 2018.
- 327 [29] K. Kobayashi, “Gradual activation of the response regulator DegU controls serial
328 expression of genes for flagellum formation and biofilm formation in *Bacillus subtilis*,”
329 *Mol. Microbiol.*, vol. 66, no. 2, pp. 395–409, 2007, doi: 10.1111/j.1365-
330 2958.2007.05923.x.
- 331 [30] C. L. Moore *et al.*, “Comparative evaluation of epidemiology and outcomes of methicillin-
332 resistant Staphylococcus aureus (MRSA) USA300 infections causing community- and
333 healthcare-associated infections,” *Int. J. Antimicrob. Agents*, vol. 34, no. 2, pp. 148–155,
334 2009, doi: 10.1016/j.ijantimicag.2009.03.004.
- 335 [31] J. T. Smith, E. M. Eckhardt, N. B. Hansel, T. R. Eliato, I. W. Martin, and C. P. Andam,
336 “Genomic epidemiology of methicillin-resistant and -susceptible Staphylococcus aureus
337 from bloodstream infections,” *BMC Infect. Dis.*, vol. 21, no. 1, pp. 1–14, 2021, doi:
338 10.1186/s12879-021-06293-3.
- 339 [32] I. A. Tickler, R. V. Goering, J. R. Mediavilla, B. N. Kreiswirth, and F. C. Tenover, “Continued
340 expansion of USA300-like methicillin-resistant Staphylococcus aureus (MRSA) among
341 hospitalized patients in the United States,” *Diagn. Microbiol. Infect. Dis.*, vol. 88, no. 4,
342 pp. 342–347, 2017, doi: 10.1016/j.diagmicrobio.2017.04.016.
- 343 [33] S. N. Thiede *et al.*, “Genomic Epidemiology Suggests Community Origins of Healthcare-
344 Associated USA300 Methicillin-Resistant Staphylococcus aureus,” *J. Infect. Dis.*, vol. 226,
345 no. 1, pp. 157–166, 2022, doi: 10.1093/infdis/jiac056.
- 346 [34] B. W. Jenkins TC, McCollister BD, Sharma R, McFann KK, Madinger NE, Barron M,
347 Bessesen M, Price CS, “Epidemiology of healthcare-associated bloodstream infection
348 caused by USA300 strains of methicillin-resistant Staphylococcus aureus in 3 affiliated
349 hospitals,” *Infect Control Hosp Epidemiol.*, vol. 30, no. 3,
350 pp. 233–41, 2009, doi: 10.1086/595963.
- 351 [35] M. Pardos De La Gandara *et al.*, “MRSA causing infections in hospitals in Greater
352 Metropolitan New York: Major shift in the dominant clonal type between 1996 and
353 2014,” *PLoS One*, vol. 11, no. 6, pp. 1–13, 2016, doi: 10.1371/journal.pone.0156924.
- 354 [36] M. Sherwood, J., Park, M., Robben, P., Whitman, T., & Ellis, “USA300 Methicillin-Resistant
355 Staphylococcus aureus Emerging as a Cause of Bloodstream Infections at Military
356 Medical Centers,” *Infect. Control Hosp. Epidemiol.*, vol. 34, no. 4, pp. 393–399, 2013, doi:
357 10.1086/669866.
- 358 [37] M. Z. David *et al.*, “Staphylococcus aureus bacteremia at 5 US Academic Medical Centers,
359 2008-2011: Significant geographic variation in community-onset infections,” *Clin. Infect.
360 Dis.*, vol. 59, no. 6, pp. 798–807, 2014, doi: 10.1093/cid/ciu410.
- 361 [38] L. O. Hudson *et al.*, “Diversity of Methicillin-Resistant Staphylococcus aureus (MRSA)
362 Strains Isolated from Inpatients of 30 Hospitals in Orange County, California,” *PLoS One*,
363 vol. 8, no. 4, pp. 1–8, 2013, doi: 10.1371/journal.pone.0062117.
- 364 [39] D. A. Talan *et al.*, “Comparison of staphylococcus aureus from skin and soft-tissue
365 infections in us emergency Department patients, 2004 and 2008,” *Clin. Infect. Dis.*, vol.
366 53, no. 2, pp. 144–149, 2011, doi: 10.1093/cid/cir308.
- 367 [40] K. A. Nichol *et al.*, “Characterization of MRSA in Canada from 2007 to 2016,” *J.*

368 *Antimicrob. Chemother.*, vol. 74, pp. IV55–IV63, 2019, doi: 10.1093/jac/dkz288.
369 [41] S. E. Crawford, M. Z. David, D. Glikman, K. J. King, S. Boyle-Vavra, and R. S. Daum,
370 “Clinical importance of purulence in methicillin-resistant *Staphylococcus aureus* skin and
371 soft tissue infections,” *J. Am. Board Fam. Med.*, vol. 22, no. 6, pp. 647–654, 2009, doi:
372 10.3122/jabfm.2009.06.090025.
373

374 **Tables**

375 Table 1. Demographic and clinical characteristics of subjects with MRSA infections and clonal
376 complexes of the causative MRSA isolates, comparing bacteremia (BSI) cases to skin and soft
377 tissue infections (SSTIs).

378

Category	SSTI n=131 (%)	BSI n=145 (%)	p-value
Race			
			p > 0.05
White	81 (62)	78 (54)	
Black	43 (33)	58 (40)	
Asian	2 (2)	2 (1)	
Other	5 (4)	7 (5)	
Gender			
			p > 0.05
Female	62 (47)	70 (48)	
Male	69 (53)	75 (52)	
Epidemiologic Type			
			p < 0.001
HA	5 (5)	34 (23)	
CA	64 (49)	17 (12)	
HACO	62 (47)	94 (65)	
Site of Diagnosis			
			p < 0.001
Emergency Department patient	35 (27)	4 (3)	
Inpatient	36 (27)	138 (95)	
Outpatient	60 (46)	3 (2)	
Age (years)			
			p > 0.05
<50	52 (40)	57 (40)	
>50	79 (60)	86 (60)	
Clonal complex or ST			
			p < 0.001
CC8	102 (78)	79 (55)	
CC5	20 (15)	55 (39)	
CC1	1 (<1)	0	
CC6	1 (<1)	0	
CC22	2 (1)	0	
CC30	1 (<1)	2 (1)	
CC45	1 (<1)	0	
CC59	1 (<1)	0	
CC71	1 (<1)	0	
CC72	0	6 (4)	
CC78	0	2 (1)	
ST87	0	1 (<1)	

380 Table 2. Types of skin and soft tissue infections (SSTIs) and sources of bacteremia (BSI) in this
381 study

Type of SSTI n=131 (%)	
Abscess	68 (52%)
Surgical Site Infection	18 (14%)
Infected Wounds	16 (12%)
Cellulitis	15 (11%)
Folliculitis	3 (2%)
Impetigo	3 (2%)
Pustule	3 (2%)
Otitis Externa	1 (<1%)
Paronychia	1 (<1%)
Cyst	1 (<1%)
Pyomyositis	1 (<1%)
Tenosynovitis	1 (<1%)
Type of BSI n=145 (%)	
Skin site	27 (19%)
Central venous catheter infection	20 (14%)
Surgical site	7 (5%)
Device infection	5 (3%)
Arteriovenous Graft	4 (3%)
Respiratory source	3 (2%)
Urinary source	3 (2%)
Other	5 (3%)
Unknown	71 (49%)

382

383

384

385

386 Table 3. Susceptibility of MRSA to antimicrobial agents, comparing skin and soft tissue infection
 387 (SSTI) isolates to bacteremia (BSI) isolates

Drug name	SSTI n=131 (%)		BSI n=145 (%)	
	Number tested	Susceptible	Number test	Susceptible
Ampicillin	130	0	145	0
Cefazolin	130	0	145	0
Penicillin	131	0	145	0
Oxacillin	131	0	145	0
Gentamicin	131	126 (96)	144	142 (99)
Ciprofloxacin	131	38 (29)	144	45 (31)
Levofloxacin	131	38 (29)	145	45 (31)
Moxifloxacin	131	39 (30)	144	46 (32)
Erythromycin	131	22 (17)	145	16 (11)
Clindamycin	131	95 (73)	145	86 (59)
Quinupristin-Dalfopristin	130	130 (100)	144	144 (100)
Linezolid	130	130 (100)	144	144 (100)
Vancomycin	131	131 (100)	145	145 (100)
Tetracycline	131	120 (92)	145	125 (86)
Tigecycline	131	128 (98)	145	139 (96)
Nitrofurantoin	131	129 (98)	144	144 (100)
Rifampicin	131	130 (99)	145	141 (97)
Trimethoprim/Sulfamethoxazole	131	131 (100)	145	135 (93)
Daptomycin	0	0	130	130 (100)
Ceftaroline	0	0	5	5 (100)
Cefoxitin	130	0 (0)	144	2 (1)

388
 389
 390
 391
 392
 393
 394
 395

396 Table 4. Demographic and strain data for all MRSA outbreak clusters.

Subject ID*	SSTI clusters	SSTI BSI clusters	BSI clusters	Sample Type	ST	CC	USA300/500	Source of BSI	Type of SSTI	Race	Sex	Age
S0111	3			SSTI	8	CC8	USA300	NA	Abscess	Other	Male	25-30
S0125	3			SSTI	8	CC8	USA300	NA	Infected Wounds	White	Male	55-60
S0004	7			SSTI	8	CC8	USA300	NA	Abscess	White	Male	35-40
S0112	7			SSTI	8	CC8	USA300	NA	Otitis Externa	Black	Female	50-55
S0014	8			SSTI	8	CC8	USA300	NA	Cellulitis	White	Male	65-70
S0118	8			SSTI	8	CC8	USA300	NA	Infected Wounds	Black	Male	70-75
SAB00135		1		Blood	105	CC5	NA	Skin site	NA	White	Female	55-60
SAB00138		1		Blood	105	CC5	NA	Central venous catheter infection	NA	Black	Female	45-50
S0132		1		SSTI	105	CC5	NA	NA	Cellulitis	White	Female	55-60
SAB00143		1		Blood	105	CC5	NA	Urinary source	NA	Black	Male	90-95
SAB00010		4		Blood	8	CC8	USA300	Unknown	NA	Black	Female	50-55
S0089		4		SSTI	8	CC8	USA300	NA	Infected Wounds	Other	Male	40-45
SAB00081		6		Blood	8	CC8	USA300	Central venous catheter infection	NA	Other	Female	30-35
S0040		6		SSTI	8	CC8	USA300	NA	Cellulitis	White	Female	85-90
S0024		11		SSTI	8	CC8	USA300	NA	Abscess	White	Female	70-75
SAB00048		11		Blood	8	CC8	USA300	Device infection	NA	Black	Female	60-65
SAB00098		12		Blood	8	CC8	USA300	Central venous catheter infection	NA	Black	Female	80-85
S0052		12		SSTI	8	CC8	USA300	NA	Abscess	White	Male	40-45
SAB00072		13		Blood	8	CC8	USA300	Unknown	NA	White	Male	30-35
S0094		13		SSTI	8	CC8	USA300	NA	Abscess	White	Male	75-80
S0056		15		SSTI	8	CC8	USA300	NA	Cellulitis	White	Male	30-35
SAB00121		15		Blood	8	CC8	USA300	Unknown	NA	White	Male	30-35
SAB00005		16		Blood	8	CC8	USA300	Unknown	NA	White	Female	70-75
S0013		16		SSTI	8	CC8	USA300	NA	Abscess	White	Female	50-55
SAB00008	NA		2	Blood	105	CC5	NA	Unknown	NA	Black	Male	50-55
SAB00031	NA		2	Blood	105	CC5	NA	Unknown	NA	Black	Male	65-70
SAB00082	NA		2	Blood	105	CC5	NA	Central venous catheter infection	NA	Asian	Male	45-50
SAB00065	NA		5	Blood	8	CC8	USA300	Unknown	NA	Other	Female	50-55
SAB00126	NA		5	Blood	8	CC8	USA300	Surgical site	NA	White	Male	65-70
SAB00009	NA		9	Blood	105	CC5	NA	Central venous catheter infection	NA	Black	Female	50-55
SAB00023	NA		9	Blood	105	CC5	NA	Unknown	NA	Black	Male	25-30
SAB00063	NA		10	Blood	8	CC8	USA300	Unknown	NA	White	Female	20-25
SAB00075	NA		10	Blood	8	CC8	USA300	Unknown	NA	Other	Female	40-45
SAB00047	NA		14	Blood	105	CC5	NA	Unknown	NA	Black	Female	60-65
SAB00074	NA		14	Blood	105	CC5	NA	Central venous catheter infection	NA	White	Male	45-50

397
 398 *Subject IDs presented in this table are coded to ensure the confidentiality of patient
 399 information. These codes are known exclusively to the study team and have been designed to
 400 safeguard participants' privacy.

401
 402 **Figure Legends**

403
 404 Figure 1. A) Distribution of infection types among the skin and soft tissue infections (SSTIs),
 405 stratified by clonal complex. B) Distribution of infection types among the bloodstream

406 infections (BSIs), stratified by clonal complex. C) Clonal complex distribution comparing SSTI and
407 BSI strains.


408

409 Figure 2. A) Maximum likelihood tree of all sequenced samples. Heatmap depicts clonal
410 complexes, if the samples are from a bloodstream infection (BSI), and agr group. B) CC8 cluster
411 only, C) CC5 cluster only, branch tips indicate outbreak clusters > 15 SNPs. Clusters with only BSI
412 strains are represented with a circle, clusters with only strains from skin and soft tissue
413 infections (SSTIs) are represented with a square, and clusters containing both BSI and SSTI
414 strains are represented by triangles.

415 **Figures**

416 **Figure 1.**

417



418

419

420 **Figure 2.**

